Differential Effects of Dietary Fat Content and Protein Source on Bone Phenotype and Fatty Acid Oxidation in Female C57Bl/6 Mice.
BACKGROUND
Glycomacropeptide (GMP) is a 64-amino acid glycophosphopeptide released from κ-casein during cheesemaking that promotes satiety, reduces body fat, increases bone mass and infers prebiotic and anti-inflammatory effects. The impact of adiposity and gender on bone health is unclear.


OBJECTIVE
To determine how feeding female mice diets providing 60% Fat Kcal (high-fat) or 13% Fat Kcal (control) with either GMP or casein as the protein source impacts: body composition, ex vivo fatty acid oxidation, bone (femoral) biomechanical performance, and the relationship between body composition and bone.


METHODS
Weanling female C57Bl/6 mice were fed high-fat (60% Fat Kcal) or control diets (13% Fat Kcal) with GMP or casein from 3 to 32 weeks of age with assessment of body weight and food intake. Body composition was assessed by dual-energy X-ray absorptiometry (DXA). Fatty acid oxidation was measured in liver, muscle, and fat tissues using 14C-palmitate. Plasma concentrations of hormones and cytokines were determined. Bone biomechanical performance was assessed by the 3-point bending test.


RESULTS
Female mice fed high-fat diets showed increased fatty acid oxidation capacity in both gastrocnemius muscle and brown adipose tissue compared to mice fed the control diets with a lower fat content. Despite increased fat mass in mice fed the high-fat diets, there was little evidence of glucose impairment or inflammation. Mice fed the high-fat diets had significantly greater total body bone mineral density (BMD), femoral BMD, and femoral cross-sectional area than mice fed the control diets. Femora of mice fed the high-fat diets had increased yield load and maximum load before fracture, consistent with greater bone strength, but reduced post-yield displacement or ductility, consistent with bone brittleness. Female mice fed a high-fat GMP diet displayed increased fat oxidation capacity in subcutaneous fat relative to mice fed the high-fat casein diet. Regardless of dietary fat content, GMP increased total body bone mineral content and femur length. The prebiotic properties of GMP may mediate the beneficial effects of GMP on bone.


CONCLUSIONS
Female mice adapt to high-fat feeding by increasing oxidative capacity in muscle tissue and to a lesser extent brown adipose tissue. High-fat feeding in female mice leads to development of a bone phenotype where femora show increased BMD and are stronger, yet more brittle. The increased brittleness of bone was associated with increased body fat content due to high-fat feeding. In summary, high-fat feeding in female mice increases mineralization of bone, but negatively impacts bone quality resulting in brittle bones.
Department of Nutritional Sciences, University of Wisconsin-Madison, Madison, Wisconsin, United States of America.
Emily A
EA
Sawin
Department of Nutritional Sciences, University of Wisconsin-Madison, Madison, Wisconsin, United States of America.
Bridget M
BM
Stroup
Department of Nutritional Sciences, University of Wisconsin-Madison, Madison, Wisconsin, United States of America.
Sangita G
SG
Murali
Department of Biochemistry, University of Wisconsin-Madison, Madison, Wisconsin, United States of America.
Lucas M
LM
O'Neill
Department of Biochemistry, University of Wisconsin-Madison, Madison, Wisconsin, United States of America.
James M
JM
Ntambi
Department of Nutritional Sciences, University of Wisconsin-Madison, Madison, Wisconsin, United States of America.
Denise M
http://orcid.org/0000-0002-2260-5313
DM
Ney
D000818:Animals; D001696:Biomechanical Phenomena; D001823:Body Composition / Q000187:drug effects; D015519:Bone Density / Q000187:drug effects; D002364:Caseins / Q000008:administration & dosage; D004041:Dietary Fats / Q000008:administration & dosage; D004734:Energy Metabolism / Q000187:drug effects*; D005227:Fatty Acids / Q000378:metabolism*; D005260:Female; D005269:Femur / Q000187:drug effects / Q000254:growth & development*; D006801:Humans; D051379:Mice; D009765:Obesity / Q000178:diet therapy* / Q000378:metabolism / Q000503:physiopathology; D010084:Oxidation-Reduction; D010446:Peptide Fragments / Q000008:administration & dosage; D010641:Phenotype
D002364:Caseins; D004041:Dietary Fats; D005227:Fatty Acids; D010446:Peptide Fragments; C065989:caseinomacropeptide
Nature. 2010 Mar 4;464(7285):121-5
20203611
Appetite. 2009 Apr;52(2):388-95
19101599
Trends Endocrinol Metab. 2015 Feb;26(2):69-74
25497348
J Clin Densitom. 2004 Fall;7(3):326-33
15319505
Cell. 2007 Sep 7;130(5):811-23
17803905
Food Chem Toxicol. 2013 Jun;56:1-7
23416648
Obes Rev. 2010 Jan;11(1):11-8
19656312
Annu Rev Nutr. 2001;21:193-230
11375435
J Bone Miner Metab. 2012 Jan;30(1):47-53
21644057
J Clin Endocrinol Metab. 2009 Sep;94(9):3387-93
19531595
Trends Immunol. 2004 Jan;25(1):4-7
14698276
Biochem Biophys Res Commun. 1965 May 3;19:452-5
14338991
Science. 2000 Sep 1;289(5484):1508-14
10968781
Br J Nutr. 2008 Jul;100(1):88-93
18062832
Am J Physiol Endocrinol Metab. 2012 Apr 1;302(7):E885-95
22297302
Cell. 2012 Jul 20;150(2):366-76
22796012
Cell Metab. 2006 Nov;4(5):341-8
17084709
Am J Pathol. 2007 Feb;170(2):427-35
17255310
Physiol Behav. 2009 Jan 8;96(1):162-8
18948128
Br J Pharmacol. 2008 Jun;154(4):825-32
18536735
J Acad Nutr Diet. 2012 Aug;112(8):1201-10
22818728
Nat Med. 2007 Jul;13(7):791-801
17618270
J Agric Food Chem. 2011 Jun 22;59(12):6501-10
21553845
Br J Nutr. 2010 Jul;104(2):286-90
20205966
Am J Physiol Gastrointest Liver Physiol. 2015 Oct 1;309(7):G590-601
26251473
Int J Obes. 1983;7(2):99-107
6862762
Bone. 2002 Nov;31(5):547-55
12477567
FASEB J. 2009 Jul;23(7):2142-54
19261723
Mol Genet Metab. 2010 Aug;100(4):303-8
20466571
Eur J Nutr. 2012 Oct;51(7):861-70
22042005
J Bone Miner Res. 2008 Feb;23(2):189-98
17922610
J Clin Endocrinol Metab. 2006 Jul;91(7):2534-41
16621904
Nutrition. 2008 Jul-Aug;24(7-8):625-31
18485667
J Bone Miner Res. 2012 Jan;27(1):1-10
23348758
Diabetes. 2002 May;51(5):1477-84
11978645
J Nutr. 2004 Apr;134(4):989S-95S
15051859
Bone. 2010 Jan;46(1):217-25
19853069
J Nutr. 2004 Apr;134(4):996S-1002S
15051860
EMBO J. 2007 Apr 4;26(7):1913-23
17347648
Cell Signal. 2007 Jan;19(1):185-93
16887331
Physiol Behav. 2008 Jan 28;93(1-2):379-87
17964616
J Nutr. 2010 Nov;140(11):2014-9
20881082
Bone. 1998 Nov;23(5):399-407
9823445
Br J Nutr. 2014 May 28;111(10):1811-21
24506951
Arch Biochem Biophys. 2010 Nov 1;503(1):20-7
20599663
Regul Pept. 2000 Aug 25;92(1-3):73-8
11024568
Methods. 2001 Dec;25(4):402-8
11846609
Am J Physiol Endocrinol Metab. 2014 Jan 1;306(1):E14-27
24169045
Endocrinology. 2013 Mar;154(3):1021-8
23364948
Br J Pharmacol. 2015 Jun;172(11):2782-98
25559882
Regul Pept. 2010 Jan 8;159(1-3):129-36
19761803
Proc Natl Acad Sci U S A. 2000 Nov 7;97(23):12735-40
11070087
Dev Biol (Basel). 2008;132:391-398
18817332
Diabetes. 2009 Mar;58(3):550-8
19073774
PLoS One. 2012;7(9):e45165
23028819
Endocrinology. 2009 May;150(5):2161-8
19179442
Bone. 2011 Mar 1;48(3):647-53
20969983
Diabetes. 2007 Aug;56(8):2085-92
17519422
BMC Musculoskelet Disord. 2005 Feb 23;6:11
15727686
PLoS One. 2012;7(9):e46057
23049932
Am J Clin Nutr. 2008 Jun;87(6):1602-5
18541546